FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population August 3, 2020 Auto Bot BioPharma, biopharma nl, diffuse large B-cell lymphoma, Germany, Incyte, MorphoSys, Oncology, tafasitamab 0 The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.